All In Biotech

Drug Trial Radar · NCT03078907

Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.

A Multi-center, Double-blind, Placebo-controlled Phase 4 Study in Patients With Pulmonary Arterial Hypertension to Assess the Effect of Selexipag on Daily Life Physical Activity and Patient's Self-reported Symptoms and Their Impacts

Last checked: Nov 20, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

108

Actual

Start

Nov 8, 2017

Primary completion

Feb 10, 2020

Study completion Feb 10, 2020

Sponsor

Lead sponsor
ActelionJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Mar 14, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the effect of selexipag on the physical activity of patients with pulmonary arterial hypertension (PAH) in their daily life, by using a wearable wrist device (actigraph). The actigraph will collect data on daily life physical activity in the patient's real environment. In addition, the PAH symptoms and their impacts will be assessed by using an electronic patient reported outcome measure in the patient's real environment. Patients will be assigned randomly to either selexipag or placebo.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • SelexipagDrug

    Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.

  • PlaceboDrug

    Matching film coated tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 24 in Actigraphy Assessed Daily Life Physical Activity (DLPA) for Variables Expressed in MinutesTime frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
  2. Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Percentage (%)Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
  3. Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Counts Per Minute (Counts/Minute)Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
  4. Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in CountsTime frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
  5. Change From Baseline to Week 24 in Actigraphy DLPA for Variable Expressed in Step CountsTime frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
  6. Change From Baseline to Week 24 in Actigraphy DLPA for Variables Expressed in Step Counts/MinuteTime frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
  7. Change From Baseline to Week 24 in Total Sleep Time (TST)Time frame: Baseline and Week 24 (data analysis was done during 14-Days each for Baseline and for Week 24 and mean value reported)
  8. Change From Baseline to Week 24 in Wake After Sleep Onset (WASO)Time frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)
  9. Change From Baseline to Week 24 in Number of AwakeningsTime frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)
  10. Change From Baseline to Week 24 in Sleep Efficiency (SE)Time frame: Baseline and Week 24 (data collection was done during 14-Days each for Baseline and for Week 24)

Locations

39 sites in 10 countries. Site status is shown where the registry gives one.

  • LA Biomedical Research Institute

    Torrance, California

  • Northside Hospital

    Atlanta, Georgia

  • Kentuckiana Pulmonary Research Center

    Louisville, Kentucky

  • Tufts Medical Center, Pulmonary/Critical Care & Sleep

    Boston, Massachusetts

  • University of Nebraska Medical Center, Pulmonary, Critical Care & Sleep Medicine Division

    Omaha, Nebraska

  • NYU Winthrop Hospital

    Mineola, New York

  • UNC Pulmonary Speciality Clinic

    Chapel Hill, North Carolina

  • Duke University School of Medicine, Duke Pulmonary Vascular Disease center

    Durham, North Carolina

  • University of Cincinnati, Heart, Lung and Vascular Institute

    Cincinnati, Ohio

  • CCF- Akron General Medical Hospital

    Cleveland, Ohio

  • Integris Baptist Medical Center

    Oklahoma City, Oklahoma

  • University of Pennsylvania, Pulmonary Vascular Disease Program

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center, Care Medicine

    Nashville, Tennessee

  • Methodist Clinical Trials

    San Antonio, Texas

  • University of Texas Health Science Center (San Antonio)

    San Antonio, Texas

  • Medizinische Universität Innsbruck (MUI), Abt. für Pneumologie, Haus 2

    Innsbruck, Austria

  • Krankenhaus der Elisabethinen, Servicestelle Klinische Studien

    Linz, Austria

  • Hôpital Bicêtre, ervice de Pneumologie et Réanimation respiratoire

    Le Kremlin-Bicêtre, France

  • CHRU de Lille - Hôpital Albert Calmette, Service de cardiologie

    Lille, France

  • Hospital Larrey CHU de Toulouse

    Toulouse, France

  • Herzzentrum der Universität zu Köln, Klinik III für Innere Medizin

    Cologne, Germany

  • Universitätsklinikum Giessen

    Giessen, Germany

  • Universitätsklinikum Leipzig AöR, Abteilung Pneumologie

    Leipzig, Germany

  • Katholisches Klinikum Lünen/Werne GmbH, Haus E

    Lünen, Germany

  • Mater Misericordiae University Hospital

    Dublin, Ireland

  • Oslo University Hospital, dept of cardiology

    Oslo, Norway

  • Centro Hospitalar e Universitário de Coimbra, Serviço de Cardiologia

    Coimbra, Portugal

  • Hospital Geral de Santo António-DEFI

    Porto, Portugal

  • Sahlgrenska University Hospital, Gothenburg

    Gothenburg, Sweden

  • Skåne University Hospital, VO Hjärt och Lungmedicin

    Lund, Sweden

  • Kantonsspital St. Gallen, Klinik für Pneumologie und Schlafmedizin

    Sankt Gallen, Switzerland

  • Universitaetsspital Zurich, Klinik für Pneumologie C HOER 11

    Zurich, Switzerland

  • Papworth Hospital, Pulmonary Vascular Disease Unit

    Cambridge, United Kingdom

  • Golden Jubilee National Hospital, Scottish Pulmonary Vascular Unit

    Clydebank, United Kingdom

  • The Royal Free Hospital, Cardiology Department

    London, United Kingdom

  • Royal Brompton Hospital, Hypertension

    London, United Kingdom

  • Hammersmith Hospital

    London, United Kingdom

  • Freeman Hospital, Cardiothoracic Department

    Newcastle upon Tyne, United Kingdom

  • Royal Hallamshire Hospital, Pulmonary Vascular Medicine

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.